Researchers at Johns Hopkins have identified claudin-4 as the receptor protein used by Bacteroides fragilis toxin (BFT) to damage the colon. This discovery, which explains how the toxin initiates inflammation linked to colorectal cancer, was successfully countered in mouse models using a molecular decoy, opening a new path for future preventive therapies.
Researchers at the Johns Hopkins Kimmel Cancer Center have identified a critical mechanism that explains how the Bacteroides fragilis toxin (BFT) interacts with the human gut to promote colorectal cancer. For two decades, the scientific community has been aware that BFT compromises the intestinal barrier, leading to chronic inflammation and tumor formation. However, the exact docking point—the receptor where the toxin latches onto cells to initiate this damage—was previously unknown.
By using genome-wide CRISPR screening, the research team discovered that the toxin specifically targets claudin-4, a protein responsible for maintaining tight junctions between intestinal cells. The findings revealed that BFT does not act directly on its primary structural target, E-cadherin. Instead, it must first bind to claudin-4, which then triggers the degradation of the E-cadherin protein, effectively breaking down the protective intestinal wall.
To test the potential for therapeutic intervention, the researchers developed a molecular decoy modeled after the claudin-4 protein. In preclinical studies, these decoys were introduced to intercept the toxin before it could attach to healthy intestinal cells. The experiment, which was conducted in collaboration with Harvard Medical School, successfully prevented toxin-induced damage in mouse models.
While these results offer a significant advancement in understanding the biology of colorectal cancer, it is important to note that this is early-stage research. The study, published in the journal Nature, is limited to preclinical models. The development of a functional human therapy requires a long and rigorous process, including the creation of stable biologics or small-molecule drugs that can be safely administered to patients. As Johns Hopkins University is an academic and research institution, there are no stock price movements, financial results, or commercial products associated with this finding.
Future research efforts will likely focus on the challenges of translating this molecular decoy strategy into human applications. The primary hurdles will involve ensuring that any future drug can target the toxin specifically without disrupting the natural function of claudin-4 in the body. Researchers will also need to determine if this approach can be used as a preventative measure for high-risk individuals, though widespread medical use remains a long-term goal.